Russia applies its first domestic mRNA cancer vaccine, offering a tailored immune-based therapy.
A Russian patient receives the country’s first mRNA-based cancer vaccine.
Russia has administered its first domestically produced personalized cancer vaccine, offering a new treatment approach for patients facing aggressive cancers with limited conventional options.
The Ministry of Health announced Wednesday that a 60-year-old melanoma patient from Kursk province received Neooncovac at the National Medical Research Center for Radiology (NMIts radiologii). The vaccine, developed alongside Moscow’s Gamaleya Center, uses messenger RNA (mRNA) technology and is tailored to each patient’s tumor profile.
The treatment begins with three doses over the first two weeks, followed by one dose every 21 days, totaling ten doses. Neooncovac is prepared individually in a laboratory immediately before administration.
Russia delivered its 1st personalized cancer vaccine, Neooncovac, to a melanoma patient at the National Medical Research Center for Radiology.
— Russian Embassy in Kenya/Посольство России в Кении (@russembkenya) April 2, 2026
A 60-year-old from the Kursk region received mRNA-based treatment alongside immunotherapy.
Significant advance in precision oncology💉 pic.twitter.com/fau8dOP6gh
Andréi Kaprin, director general of NMIts radiologii, emphasized the vaccine represents “a paradigm shift. It is not only a matter of treating the disease, but of teaching the immune system to identify and eliminate cells that pose a real risk.” Officials plan to expand its use to other cancers if results prove effective in melanoma.
Text Reads: The Russian Ministry of Health announced on Wednesday the treatment of the first patient with a personalized cancer vaccine. This domestically produced drug represents a breakthrough in the fight against cancer. 🔴 Named Neooncovac, this mRNA vaccine was administered to a 60-year-old patient with cutaneous melanoma. It is proposed as an essential measure to control the disease, given the risk of progression. 🔴 Andrey Kaprin, Director General of the National Institute of Medical Sciences (NMIC) for Radiology, emphasized that the vaccine “teaches” the immune system to identify and eliminate risk cells.
Denís Logunov, director of the Gamaleya Center, explained that “advanced computational methods and genetic constructs” were incorporated in the vaccine’s design. He highlighted that collaboration between oncologists and vaccine specialists was key to bringing the treatment to patients.
mRNA, or ribonucleic acid, transmits genetic instructions from DNA to ribosomes. By analyzing a patient’s tumor, Neooncovac “teaches” the immune system to recognize and target cancerous cells, making the vaccine fully personalized.
Russian health authorities say Neooncovac marks a major step in individualized cancer care, with potential applications beyond melanoma as clinical research continues.
Author: MK
Source: RT / Sputnik
0 Comentarios